Tests BMS-986523 alone and with other cancer drugs in advanced solid tumors
Tests the drug BMS-986523, alone or combined, in adults with advanced solid cancers.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Key facts
- Where
- Badalona and Hortaleza, SpainSee the 2 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumours that cannot be removed by surgery or have spread, and that have a known KRAS change.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Locally advanced tumour that cannot be removed by surgery, or metastatic solid tumour, confirmed under the microscope. Conditions listed: non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma.
- Earlier treatment
- Must have already had the standard treatments set by the protocol, or cannot have them, or decline them after being given enough information.
- Biomarker or test result
- A known KRAS change (mutation or amplification). For Arm D, PD-L1 expression of ≥50%.
Main reasons for not taking part
- Untreated metastases in the brain or spinal cord (central nervous system)
- Another cancer needing treatment now, or another cancer active within the past 2 years
- Past or current interstitial lung disease or active non-infectious pneumonitis (past radiation pneumonitis in the radiation field is allowed)
- Past severe skin reactions such as Stevens-Johnson Syndrome or toxic epidermal necrolysis
Read by machine on 12 November 2026.
Where in Spain
- Badalona, Barcelona [Barcelona]Hospital not named in the registryContact: Site 0006Not yet recruiting
- Hortaleza, MadridHospital not named in the registryContact: Site 0008Not yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07223047
- Record updated
- 28 May 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignanciesRead full original descriptionShow less
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Inclusion: Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification); Participants must, for Arm D, have a PD-L1 expression (≥50%); Participants must have previously received, be ineligible for, or decline (after having been provided adequate information to make an informed decision) the protocol defined standard of care (SoC) treatments.
Exclusion: Participants must not have a history of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN); Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment; Participants must not have a history of, or any evidence of, interstitial lung disease or active, non-infectious pneumonitis. A history of radiation pneumonitis in the radiation field is permitted; Participants must not have untreated central nervous system (CNS) metastases; Other protocol-defined Inclusion/Exclusion criteria apply.